May 15 |
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
|
May 9 |
Olema Pharmaceuticals GAAP EPS of -$0.56 beats by $0.02
|
May 8 |
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
May 8 |
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
|
May 1 |
Olema Oncology to Participate in Upcoming Investor Conferences in May
|
Apr 8 |
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
|
Apr 5 |
Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks
|
Mar 28 |
Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path
|
Mar 11 |
Olema Pharmaceuticals GAAP EPS of -$0.49
|
Mar 11 |
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
|